Investor Presentation Full Year 2021
82
Investor presentation
Full year 2021
Ziltivekimab phase 2b RESCUE trial was successfully completed
In the RESCUE trial, zilti QM showed reduction in hsCRP at all dose
levels
■placebo ziltivekimab 7.5 mg ziltivekimab 15 mg
ziltivikemab 30 mg
% change¹
12 weeks of treatment
End of treament²
0%
-3%
-5%
-20%
-40%
-60%
-80%
-77%
-100%
-88%*
*
-92%
-79%
*
-91%* -93%*
Zilti QM showed reductions in inflammation biomarkers³
Zilti QM appeared to have a safe and well-tolerated profile
Addressing the residual risk of CVD for more than 5 million patients
with ASCVD, CKD, and inflammation4
The phase 3 cardiovascular outcomes trial was initiated as of Q3
2021
1 Primary endpoint was the median percent change in hsCRP, * Indicates statistical significance, p < .0001
2 End of treatment is defined as the average of values at week 23 and week 24
3 Inflammation biomarkers include: Fibrinogen, serum amyloid A, haptoglobin and NTproBNP
4 Inflammation is defined as c-reactive protein levels greater than 2
Zilti: Ziltivekimab; QM: Once-montly; hsCRP: High-sensitivity C-reactive protein; CVD: Cardiovascular disease; ASCVD: Atherosclerotic cardiovascular disease; CKD: Chronic kidney disease
Novo Nordisk®View entire presentation